AUTHORS
Brittany Knick Ragon, MD, Jennifer Cornette2, Dalton Cox, MD3, Heather Tucker, BSN, RN, CEN, CAVRN4, Kathy Barnard5, Joseph Rodriguez6, Kipsy Prewett7, Leighann Mason8, Ruhi Kathane9, Jessica Salzman, MD10, Jessica Roddy11, Tamara K Moyo, MD,PhD12, Zeinab El Boghdadly, MD13, Chad Scarboro, MD14, Michael R. Grunwald, MD15
AFFILIATIONS
1 Atrium Health Levine Cancer Institute/Wake Forest University School of Medicine, Charlotte, North Carolina, United States
2 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
3 Atrium Health Carolinas Medical Center, Charlotte, North Carolina, United States
4 Atrium Health, Charlotte, North Carolina, United States
5 Atrium Health Carolinas Medical Center, Charlotte, North Carolina, United States
6 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
7 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
8 Atrium Health Carolinas Medical Center, Charlotte, North Carolina, United States
9 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
10 Atrium Health Carolinas Medical Center, Charlotte, North Carolina, United States
11 Atrium Health Carolinas Medical Center, Charlotte, North Carolina, United States
12 Atrium Health Levine Cancer Institute/Wake Forest University School of Medicine, Charlotte, North Carolina, United States
13 Atrium Health Levine Cancer Institute/Wake Forest University School of Medicine, Charlotte, North Carolina, United States
14 Atrium Health Carolinas Medical Center, Charlotte, North Carolina, United States
15 Atrium Health Levine Cancer Institute/Wake Forest University School of Medicine, Charlotte, North Carolina, United States
ABSTRACT
Background: Emergency Department (ED) utilization is common among patients (pts) with hematologic malignancies, including transplant or cell therapy recipients, due to disease- and treatment-related complications. These pts are at high risk for life-threatening complications, including neutropenic fever, sepsis, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS), requiring timely recognition and multidisciplinary management. Standard ED workflows may not address the specialized needs of this population, resulting in delays in evaluation, time-sensitive therapy, and communication with Hematology. To improve acute care delivery, we developed and implemented “Code Chemo,” a multidisciplinary ED pathway designed to standardize and expedite care for pts with hematologic malignancies presenting with high-risk complications.
Methods: Using iterative Plan-Do-Study-Act (PDSA) cycles, a multidisciplinary team including Hematology, Transplant and Cellular Therapy, Emergency Medicine, nursing, transfer center coordinators, informatics, and data specialists developed and implemented the Code Chemo pathway. The pathway included a standardized activation process, ED-specific Code Chemo order sets, a dedicated secure-chat communication channel, cross-departmental workflows, protocolized evaluation and disposition, and a quality improvement database.
Implementation was evaluated using predefined process measures, including time from ED arrival to antibiotic administration, utilization of ED Code Chemo or sepsis order sets, and the proportion of Code Chemo encounters initiated by Hematology. Time to antibiotics was compared between encounters with and without Hematology-initiated Code Chemo activation using the Mann-Whitney U test. Stakeholders met biweekly to monthly to review quality improvement data, evaluate performance against predefined targets, and refine the pathway through ongoing PDSA cycles.
Results: From implementation of the Code Chemo pathway (July 1, 2024-July 15, 2026), pts with hematologic malignancies accounted for 2,530 ED encounters, including 900 with diagnostic codes for fever, neutropenia, CRS, or ICANS. Among these encounters, an ED Code Chemo or sepsis order set was used in 322 (36%), antibiotics were administered within 90 minutes in 236 (26%), and pre-arrival communication with the ED occurred in 168 (19%).
Detailed quality improvement review was conducted during the most recent study period (November 16, 2025-July 15, 2026). During this period, 71 pts were reviewed through the quality improvement database as potential Code Chemo cases. Of these, 62 met criteria for antibiotic administration. Exclusions included antibiotic receipt prior to ED arrival (n=1), no hematologic malignancy (n=1), COVID-19 (n=1), CRS without antibiotic indication (n=3), and other reasons (n=3). Among the 62 eligible encounters, an ED Code Chemo or sepsis order set was used in 40 (65%), and antibiotics were administered within 90 minutes in 27 (43%). Across all 71 reviewed encounters, the Hematology team initiated Code Chemo in 23 pts (32%).
Among 62 eligible pts, median time to antibiotics was shorter with Hematology-initiated Code Chemo activation than those without Hematology initiation (83.5 vs. 108 minutes; Mann-Whitney U test, P=0.019).
Compared with the predefined institutional benchmark of 50%, the median monthly rate of ED Code Chemo/sepsis order set utilization was 71% (range across study months, 10%-80%), exceeding the target. Median monthly rates for antibiotic administration within 90 minutes (43%; range, 14%-60%) and Hematology-initiated Code Chemo activation (40%; range, 14%-50%) were below target. Monthly performance review informed ongoing PDSA cycles, leading to targeted provider education, introduction of overhead Code Chemo notifications, and workflow refinements.
Conclusions: Implementation of a multidisciplinary Code Chemo pathway enabled a standardized approach to ED evaluation and management of pts with hematologic malignancies presenting with high-risk complications. Hematology-initiated Code Chemo activation was associated with significantly shorter time to antibiotic administration, demonstrating the value of early multidisciplinary coordination. These findings support continued efforts to optimize pathway activation, order set utilization, and timely antibiotic administration to further improve acute care delivery for patients with hematologic malignancies.
DISCLOSURES
Brittany Knick Ragon, MD: Syndax - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Astellas - Consultancy (Includes expert testimony)